Search Results for “artificial intelligence” – Page 11 – media

Two innovative medical devices were approved for marketing

Recently, the National Medical Products Administration announced the approval of two innovative product registration applications: “Brain Surgery Planning Software” by Beijing Huake Precision Medical Technology Co., Ltd. (hereinafter referred to as Huake Precision) and “Implantable Deep Brain Neurostimulation Extension Lead” by Boston Scientific Neuromodulation Company (hereinafter referred to as Boston Scientific). Huake Precision focuses on the research and development, production and technical services of intelligent and innovative medical devices. It is a leading company in China’s innovative neurosurgery medical devices, providing comprehensive technology and product solutions for the treatment of brain diseases. It is reported that Huake Precision currently has five major product lines including the SR series of neurosurgery robots, the Q300 series of micro neurosurgery robots, the NS series of neurosurgery navigation, the Huake Hengsheng intracranial electrode series, and the LS series of magnetic resonance guided laser ablation treatment systems. It has built a full-chain technology system including ...
- Source: drugdu
- 205
- November 14, 2024
AstraZeneca’s Global CEO Responds for the First Time to the Detention of Chinese Executive

On November 12, local time, Pascal Soriot, the Global CEO of AstraZeneca, publicly responded for the first time to the detention of the company’s China President, Wang Lei. Soriot stated, “Wang Lei is discussing the matter with his lawyer, and the company does not have any new information regarding the case.” Soriot made these comments following the release of AstraZeneca’s third-quarter financial report. He emphasized, “We take issues related to the Chinese market very seriously and are taking measures to enhance compliance.” However, he denied that AstraZeneca’s headquarters lacked oversight on compliance matters. He noted that the company has over 16,000 employees in China and lamented that some individuals may succumb to “temptation” to maximize sales. Moreover, he mentioned that AstraZeneca has strengthened its compliance team in China, which consists of over 200 members, and has introduced resident compliance officers who use artificial intelligence to review expense reports from sales ...
- Source: drugdu
- 187
- November 14, 2024
Siemens Healthineers plans to sell some of its shares

Recently, according to Reuters, Ralf Thomas, Chief Financial Officer of Siemens (SIEGn. DE), stated that Siemens may sell some of its shares in Siemens Healthineers (SHLG. DE), Siemens Energy (ENR1n. DE), and Fluence (FLNC. O) to help raise funds for its acquisition of Altair. On October 30th, Siemens signed the final acquisition agreement with AI software leader Altair, with a transaction amount of up to 10.6 billion US dollars (approximately 75 billion yuan), setting a record for the largest merger and acquisition transaction in Siemens Group’s history (excluding the merger of the spin off business Siemens Healthineers). The combination of Altair’s capabilities in simulation, high-performance computing, data science, and artificial intelligence with Siemens Xcelerator (industrial software) will create the world’s most complete portfolio of artificial intelligence design and simulation products, “said Siemens President and CEO Boren 01. Siemens official response Siemens, a century old manufacturing giant originating from Europe, was ...
- Source: drugdu
- 310
- November 7, 2024
Mesenchymal stromal cells (non stem cells) have been approved by the FDA for clinical trials in the treatment of acute ischemic stroke

The world’s first allogeneic adipose derived mesenchymal stromal cells (AD MSCs) drug (NR-20201) developed by Tianshi Pharmaceutical Group Co., Ltd. for the treatment of acute ischemic stroke received clinical trial approval from the US Food and Drug Administration (FDA) on October 26, 2024. It is reported that in the process of developing NR-20201, the company used artificial intelligence to analyze single-cell transcriptomics, cell life trajectories, and fate outcomes [1,2], confirming that the AD MSCs produced by Tasly’s standard preparation process are mesenchymal stromal cells rather than mesenchymal stem cells. Based on the difference between stromal cells and stem cells, this product has unique identification criteria and a mechanism of action different from stem cells. This product selects a suitable treatment time window based on the patient’s condition, promoting effective homing of cells after intravenous infusion. After cell homing, it works synergistically with endothelial cells to activate vascular regeneration and functional ...
- Source: drugdu
- 227
- November 2, 2024
AI+Gene Therapy | Dyno partners with Roche, with a prepayment of $50 million and a total value exceeding $1 billion

On October 24, 2024, Dyno Therapeutics, a gene technology company that utilizes artificial intelligence for in vivo gene delivery, announced its second research collaboration with Roche to jointly develop the next generation of adeno-associated virus (AAV) vectors for gene therapy targeting neurological diseases.Dyno and Roche previously announced a research collaboration and licensing agreement in October 2020 for neurological disorders and liver targeted therapies. According to this new collaboration agreement, Dyno Therapeutics will provide Roche with more opportunities to utilize the company’s leading platform and sequence design technology in the field to achieve in vivo gene delivery. The existing gene therapies mainly use a small amount of naturally occurring AAV vectors, which have problems such as low delivery efficiency, pre-existing immunity, and manufacturability. To overcome these challenges, Dyno took the lead in applying artificial intelligence and high-throughput in vivo data acquisition technology to engineer the AAV virus capsid, in order to ...
- Source: drugdu
- 225
- November 1, 2024
brain-computer interface only costs $5,000

In reality, the brain-computer interface is connected to your brain at one end, extracting your ideas from the dense and complex neuronal electrical signals, and connected to external devices such as computers or machinery at the other end, directly bypassing your body to turn ideas into control signals and further execute commands. It does not need to rely on the peripheral nerves and muscle systems of your limbs to directly establish direct information exchange between the brain center and external devices. Musk released a monkey for experiment in 2021. The monkey typed a line of words “I want to eat snacks” on the computer through mind operation. This is supported by brain-computer interface technology. The cochlear implant that helps the disabled to obtain sound is the most successful and most popular technology for brain-computer interface so far. Its principle is to convert sound signals into electrical signals and transmit them ...
- Source: drugdu
- 362
- November 1, 2024
Significant Collaboration with Philips

On October 25, 2024, Medtronic and Philips announced the establishment of a strategic advocacy partnership centered on stroke care. The two companies will work together to raise awareness of the potential health and economic benefits that timely diagnosis and treatment of stroke can bring to patients, families, and society, and further expand and strengthen their partnership with the World Stroke Organization (WSO). It is reported that this cooperation has three key focus areas, including raising public awareness of stroke symptoms and the importance of timely medical treatment, improving treatment accessibility by increasing the number of hospitals with stroke treatment capabilities and providing training, and using advanced technology to create a comprehensive stroke care system to support early diagnosis, effective treatment, and postoperative monitoring. 01. Focus on stroke care, Philips and Medtronic reach cooperation It is reported that in this collaboration, Medtronic and Philips will work together to promote awareness of ...
- Source: drugdu
- 220
- October 29, 2024
Medtronic and Philips reach major cooperation

On October 25, 2024, Medtronic and Philips announced the establishment of a strategic advocacy partnership centered on stroke care. The two companies will work together to raise awareness of the potential health and economic benefits that timely diagnosis and treatment of stroke can bring to patients, families and society, and further expand and strengthen their partnership with the World Stroke Organization. It is reported that this cooperation has three key focus areas, including raising public awareness of stroke symptoms and the importance of timely medical treatment, improving treatment accessibility by increasing the number of hospitals with stroke treatment capabilities and providing training, and using advanced technology to create a comprehensive stroke care system to support early diagnosis, effective treatment and postoperative monitoring. Philips and Medtronic reach cooperation It is reported that in this cooperation, Medtronic and Philips will work together to advocate for raising awareness of the potential health and ...
- Source: drugdu
- 192
- October 29, 2024
Six major centers of the National Medical Products Administration “gathered”, and the review and approval of medical devices were fully upgraded

On October 23, with the establishment of the National Medical Products Administration Information Center in Beijing Medical Innovation Park BioPark, the six major centers of the National Medical Products Administration have been “assembled”. The six centers are the Drug Review Center of the National Medical Products Administration’s directly affiliated units, the Food and Drug Review and Inspection Center, the Drug Evaluation Center (National Drug Adverse Reaction Monitoring Center), the Medical Device Technical Review Center, the Administrative Affairs Acceptance Service and Complaint Reporting Center, and the Information Center (China Food and Drug Regulatory Data Center). Beijing Yizhuang gathers regulatory resources to provide strong guarantees for the high-quality development of biotechnology and the big health industry in terms of enterprise industry administrative approval, qualification certification, etc. In the National Bureau’s administrative affairs acceptance service hall, 10 windows are neatly arranged to handle the acceptance, consultation, charging, and certification of administrative licensing matters ...
- Source: drugdu
- 212
- October 29, 2024
AI+macrocyclic drug development | Circle Pharma completes $90 million Series D financing

On September 3, 2024, Circle Pharma, a biopharmaceutical company dedicated to discovering and developing cell permeable macrocycles as a clinical stage of a new therapy, announced the successful completion of $90 million in Series D funding, including the conversion of a convertible note.This round of financing is led by The Column Group, with new and old investors including Nextech Invest and Euclidean Capital participating. The funds raised from the financing will be used for the clinical development of Circle Pharma’s first and only similar cyclin A/B RxL inhibitor CID-078, and to support the development of the discovery project portfolio established by the company using its MXMO macrocycle platform. David Earp, CEO and Juris Doctor of Circle Pharma, said, “We are very grateful for the continued support of such a strong investor as we advance our pioneering work on macrocyclic therapy. This financing not only allows us to advance the clinical ...
- Source: drugdu
- 264
- October 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.